StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson REMICADE (infliximab) — U.S. Exports by Quarter

REMICADE (infliximab) — U.S. Exports ($M) ($M)

QuarterlyAnnual

Johnson & Johnson REMICADE (infliximab) — U.S. Exports: $12M in Q3 2026, down 36.8% from a year earlier.

Latest, Q3 2026
12
Period ended Sep 30, 2026
Change on a year earlier
-36.8%
19 in Q3 2025
History
40 quarters
Since Q4 2016
Sources
36
Documents cited below

Where the Q3 2026 figure comes from

“|| US Exports (4) | 12 | 19 | (37.1) | (37.1) | —”

Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedREMICADE (infliximab) — U.S. Exports ($M) ($M)Year on yearSource
Q3 2026Sep 30, 202612-36.8%Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Q2 2026Jun 28, 202610-70.6%Form 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗
Q1 2026Mar 29, 202618+80.0%Form 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗
Q4 2025Dec 28, 202511+22.2%Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Q3 2025Sep 28, 202519-29.6%Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Q2 2025Jun 29, 202534-2.9%Form 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗
Q1 2025Mar 30, 202510-63.0%Form 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗
Q4 2024Dec 29, 20249-74.3%Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Q3 2024Sep 29, 202427-28.9%Form 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗
Q2 2024Jun 30, 202435+6.1%Form 8-K (a2025q2exhibit991.htm, filed 2025-07-16) ↗
Q1 2024Mar 31, 202427-34.1%Form 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗
Q4 2023Dec 31, 202335-14.6%Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
Q3 2023Oct 1, 202338-2.6%Form 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗
Q2 2023Jul 2, 202333-25.0%Form 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗
Q1 2023Apr 2, 202341-48.8%Form 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗
Q4 2022Jan 1, 202341+5.1%Form 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗

Breakdown

What makes up REMICADE (infliximab) — U.S. Exports

Cite this data

StockData. (2026). Johnson & Johnson REMICADE (infliximab) — U.S. Exports ($M), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-remicade-us-exports

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.